Trevena Inc stock (US89365K1007): Trading at $0.011 amid biopharma challenges

Trevena Inc (OTCM:TRVN) shares are currently at $0.011 with a market cap of just $10,000, reflecting ongoing struggles in clinical-stage biopharma development as of recent market data.

Trevena Inc, a clinical-stage biopharmaceutical company, is trading at $0.011 per share on the OTC market with zero percent change in the latest session, according to GuruFocus as of May 2026. The tiny market capitalization of $10,000 underscores the company's challenges in advancing its pipeline of novel medicines for central nervous system disorders. Enterprise value stands at $24.11 million, with PE and PB ratios at zero, signaling no current profitability or significant book value perception by the market.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Trevena Inc
• Sector/industry: Biopharmaceuticals
• Headquarters/country: United States
• Core markets: CNS therapeutics
• Key revenue drivers: Pipeline candidates
• Home exchange/listing venue: OTC (TRVN)
• Trading currency: USD

Trevena Inc: core business model

Trevena Inc focuses on developing innovative, non-opioid therapies targeting unmet needs in central nervous system (CNS) conditions, particularly acute pain and other disorders. The company employs proprietary NaV1.7 and NaV1.8 biased ligand platforms to create compounds with improved safety profiles over traditional opioids. This approach aims to address the ongoing opioid crisis by offering alternatives with reduced abuse potential and side effects.

Headquartered in the US, Trevena has advanced several candidates through clinical stages, though commercialization remains elusive. The business model relies on milestone payments, partnerships, and potential FDA approvals to generate revenue, with no marketed products as of the latest available data from company filings.

Main revenue and product drivers for Trevena Inc

Trevena's pipeline includes OLINVYK (oliceridine), an IV opioid for acute pain approved by the FDA, which represents a key potential revenue driver despite limited market penetration. Other candidates like TRV250 for migraine and TRV734 for chronic pain are in development stages. Revenue has historically been minimal, driven by grants and collaboration deals rather than product sales.

For US investors, Trevena's exposure to the lucrative CNS market—valued in billions amid opioid alternatives demand—offers speculative appeal, though execution risks persist. Recent market data shows enterprise value at $24.11 million GuruFocus as of May 2026, highlighting the high-risk profile.

Industry trends and competitive position

The biopharma sector for non-opioid pain therapies is expanding rapidly, fueled by regulatory pressures and public health initiatives against opioid misuse. Competitors like Cara Therapeutics and Axsome Therapeutics are advancing similar CNS assets, pressuring Trevena to demonstrate clinical differentiation. Trevena's NaV platform positions it uniquely, but delays in trials have impacted valuation.

Why Trevena Inc matters for US investors

As a US-listed microcap biopharma, Trevena provides exposure to innovative CNS treatments amid a $70+ billion US pain management market. Success in pipeline advancement could yield multibagger returns, appealing to growth-oriented retail investors tracking biotech catalysts.

Conclusion

Trevena Inc remains a high-risk, speculative play in the biopharma space, with shares at $0.011 and a minuscule market cap reflecting pipeline uncertainties. While the non-opioid focus aligns with US healthcare trends, investors should monitor clinical updates and funding for potential inflection points. The company's US-centric operations and OTC listing make it accessible yet volatile for retail portfolios.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.